MX372775B - Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. - Google Patents

Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.

Info

Publication number
MX372775B
MX372775B MX2015013173A MX2015013173A MX372775B MX 372775 B MX372775 B MX 372775B MX 2015013173 A MX2015013173 A MX 2015013173A MX 2015013173 A MX2015013173 A MX 2015013173A MX 372775 B MX372775 B MX 372775B
Authority
MX
Mexico
Prior art keywords
methods
cell
cftr
chronic obstructive
obstructive pulmonary
Prior art date
Application number
MX2015013173A
Other languages
English (en)
Spanish (es)
Other versions
MX2015013173A (es
Inventor
Erik Schwiebert
Hongwu Gao
John Dixon
John Streiff
Original Assignee
Discoverybiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discoverybiomed Inc filed Critical Discoverybiomed Inc
Publication of MX2015013173A publication Critical patent/MX2015013173A/es
Publication of MX372775B publication Critical patent/MX372775B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2015013173A 2013-03-15 2014-03-14 Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. MX372775B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788353P 2013-03-15 2013-03-15
PCT/US2014/027079 WO2014152213A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Publications (2)

Publication Number Publication Date
MX2015013173A MX2015013173A (es) 2016-04-04
MX372775B true MX372775B (es) 2020-06-29

Family

ID=51581684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013173A MX372775B (es) 2013-03-15 2014-03-14 Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.

Country Status (9)

Country Link
US (1) US9815825B2 (https=)
EP (1) EP2970248B1 (https=)
JP (1) JP6514680B2 (https=)
KR (1) KR20150131309A (https=)
CN (1) CN105121437B (https=)
AU (1) AU2014240026B2 (https=)
CA (1) CA2903103C (https=)
MX (1) MX372775B (https=)
WO (1) WO2014152213A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158913A2 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
AU2013348018A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
EP2922853A4 (en) 2012-11-20 2016-11-23 Discoverybiomed Inc SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTING DEVICES
US9815825B2 (en) 2013-03-15 2017-11-14 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
MX379292B (es) 2013-03-15 2025-03-11 Discoverybiomed Inc Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas.
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
MA42488A (fr) 2015-07-24 2018-05-30 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
MA45397A (fr) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2018081381A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating cftr
CA3041675A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
MA49061A (fr) 2017-04-28 2021-04-21 Proteostasis Therapeutics Inc Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
AU2018346602B2 (en) 2017-10-06 2024-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing CFTR activity
US20190210973A1 (en) 2018-01-05 2019-07-11 The Curators Of The University Of Missouri Compounds and methods for treatment of cystic fibrosis
UA129188C2 (uk) 2018-09-09 2025-02-05 Канатфарма Аг Застосування модуляторів cftr для лікування цереброваскулярних станів
CN110156761B (zh) * 2019-06-18 2022-08-09 郑州大学 含香豆素-联苯骨架化合物、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) * 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
DE10133665A1 (de) 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003245935A1 (en) 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
CN101076332A (zh) 2004-10-13 2007-11-21 Ptc医疗公司 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途
EP2402323A3 (en) * 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
JP2008515986A (ja) * 2004-10-13 2008-05-15 ワイス N−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
CN101351208A (zh) 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
US20090012148A1 (en) * 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
EP2581451B1 (en) * 2007-12-13 2016-03-09 Indiana University Research and Technology Corporation Compounds for inhibiting mammalian s-nitrosoglutathione reductase
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
ITMI20111068A1 (it) 2011-06-14 2012-12-15 Azienda Ospedaliera Universitaria I Ntegrata Di Ve Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
US9815825B2 (en) 2013-03-15 2017-11-14 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
MX379292B (es) 2013-03-15 2025-03-11 Discoverybiomed Inc Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas.

Also Published As

Publication number Publication date
EP2970248A4 (en) 2017-01-11
MX2015013173A (es) 2016-04-04
EP2970248A2 (en) 2016-01-20
JP2016515131A (ja) 2016-05-26
WO2014152213A2 (en) 2014-09-25
EP2970248B1 (en) 2020-04-22
JP6514680B2 (ja) 2019-05-15
AU2014240026B2 (en) 2018-06-14
CA2903103A1 (en) 2014-09-25
AU2014240026A1 (en) 2015-08-20
US9815825B2 (en) 2017-11-14
CA2903103C (en) 2020-06-09
CN105121437A (zh) 2015-12-02
US20160024065A1 (en) 2016-01-28
HK1218420A1 (en) 2017-02-17
KR20150131309A (ko) 2015-11-24
CN105121437B (zh) 2018-12-04
WO2014152213A3 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
MX372775B (es) Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.
WO2014081821A3 (en) Small Molecule Bicyclic and Tricyclic CFTR Correctors
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
MX2018000688A (es) Triciclicos sustituidos y metodo para usarlos.
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122292T1 (el) Ενωσεις και μεθοδοι για αντιϊικη αγωγη
CY1118823T1 (el) Παραγωγα πυριδινης και πυραζινης για την θεραπευτικη αντιμετωπιση της χρονιας αποφρακτικης πνευμονοπαθειας
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX389354B (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
JOP20240037A1 (ar) مركبات الإندول وطرق الاستخدام
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
HK1217092A1 (zh) 治疗性化合物及其用途
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA201692298A1 (ru) Производные карбоксамидов
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
ECSP16078100A (es) Nuevo uso de n,n -2-bis- mercaptoetil isoftalamida

Legal Events

Date Code Title Description
FG Grant or registration